Rotow, Julia K <br/><br/>
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.  [electronic resource] 

 -  Clinical lung cancer  03 2019 
 - e137-e141 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1938-0690 
<br/><br/><label>Standard No.: </label>10.1016/j.cllc.2018.11.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--diagnosis<br/>Antineoplastic Agents--therapeutic use<br/>Crizotinib--therapeutic use<br/>Exons--genetics<br/>Female<br/>Humans<br/>Lung Neoplasms--diagnosis<br/>Middle Aged<br/>Mutation--genetics<br/>Neoadjuvant Therapy<br/>Prognosis<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proto-Oncogene Proteins c-met--genetics<br/>Remission Induction<br/>Treatment Outcome